KNBIFKane Biotech Inc.
The schedule
- Tue6Oct
Given the extremely limited cash reserves as of the most recent filings, Kane Biotech will likely need to execute a dilutive financing round, convertible debt issuance, or strategic restructuring to maintain operations.
- Fri26Feb
Estimated Q3 2026 earnings update. Investors will be evaluating the impact of any Q4 capital maneuvers and assessing sequential revenue progression after an erratic multi-quarter top line.
- Wed24Mar
Full-year 2026 results. The focus will be on the company's ability to survive another fiscal year, its ongoing debt obligations, and any potential commercial pipeline monetization.
- Fri28May
- Fri27Aug
Past
- Fri28Aug
Estimated Q2 2026 earnings announcement. Focus will be squarely on the cash runway, as Q1 ended with just $396K in cash against $1.92M in debt and heavy operating losses.